Shilpa Medicare launches generic Axitinib to treat advanced kidney cancer
AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).
Karnataka: Shilpa Medicare Limited has launched the Indian branded generic of Axitinib, a tyrosine kinase inhibitor drug with a brand name AXISHIL.
AXISHIL is available as 1 mg & 5 mg tablets in a pack of 14's Tablets in one bottle.
AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).
This novel targeted therapy attacks cancer cells without damaging normal cells, thus causing fewer side effects. There has been a significant improvement in survival rates in patients with advanced renal cancer due to the advent of this novel targeted therapy.
Currently, the monthly therapy cost of innovator is approximately 1.66 Lacs and with the launch of AXISHIL, the monthly cost of treatment will be reduced drastically to Rs. 14940/-.
Driving the Vision of Shilpa Medicare of "Innovating for affordable healthcare", AXISHIL is being launched to provide global quality Indian Brand with greater affordability to cancer patients. Today there are around 17,000 to 21,000 new patients in India who needs Axitinib and can be benefited by AXISHIL tablets says Mr Sundeip Bhatia, Business Head Formulations India.
